Literature DB >> 26974268

Allogeneic transplant for FLT3-ITD+ AML: room for improvement.

A E Perl1, S M Luger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26974268     DOI： 10.1038/bmt.2016.37

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  18 in total

1.  Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.

Authors:  A Renneville; N Boissel; O Nibourel; C Berthon; N Helevaut; C Gardin; J-M Cayuela; S Hayette; O Reman; N Contentin; D Bordessoule; C Pautas; S de Botton; T de Revel; C Terre; P Fenaux; X Thomas; S Castaigne; H Dombret; C Preudhomme
Journal:  Leukemia       Date:  2012-01-13       Impact factor: 11.528

2.  Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.

Authors:  Martin Bornhäuser; Thomas Illmer; Markus Schaich; Silke Soucek; Gerhard Ehninger; Christian Thiede
Journal:  Blood       Date:  2007-03-01       Impact factor: 22.113

3.  Clinical implications of FLT3 mutations in pediatric AML.

Authors:  Soheil Meshinchi; Todd A Alonzo; Derek L Stirewalt; Michel Zwaan; Martin Zimmerman; Dirk Reinhardt; Gertjan J L Kaspers; Nyla A Heerema; Robert Gerbing; Beverly J Lange; Jerald P Radich
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

4.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

Authors:  Salut Brunet; Myriam Labopin; Jordi Esteve; Jan Cornelissen; Gerard Socié; Anna P Iori; Leo F Verdonck; Liisa Volin; Alois Gratwohl; Jorge Sierra; Mohamad Mohty; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

6.  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

Authors:  Richard F Schlenk; Sabine Kayser; Lars Bullinger; Guido Kobbe; Jochen Casper; Mark Ringhoffer; Gerhard Held; Peter Brossart; Michael Lübbert; Helmut R Salih; Thomas Kindler; Heinz A Horst; Gerald Wulf; David Nachbaur; Katharina Götze; Alexander Lamparter; Peter Paschka; Verena I Gaidzik; Veronica Teleanu; Daniela Späth; Axel Benner; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2014-09-30       Impact factor: 22.113

7.  No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

Authors:  Rosemary E Gale; Robert Hills; Panagiotis D Kottaridis; Sivatharsini Srirangan; Keith Wheatley; Alan K Burnett; David C Linch
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

8.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

Authors:  Marta Pratcorona; Salut Brunet; Josep Nomdedéu; Josep Maria Ribera; Mar Tormo; Rafael Duarte; Lourdes Escoda; Ramon Guàrdia; M Paz Queipo de Llano; Olga Salamero; Joan Bargay; Carmen Pedro; Josep Maria Martí; Montserrat Torrebadell; Marina Díaz-Beyá; Mireia Camós; Dolors Colomer; Montserrat Hoyos; Jorge Sierra; Jordi Esteve
Journal:  Blood       Date:  2013-02-01       Impact factor: 22.113

9.  Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.

Authors:  Michael R Grunwald; Li-Hui Tseng; Ming-Tseh Lin; Keith W Pratz; James R Eshleman; Mark J Levis; Christopher D Gocke
Journal:  Biol Blood Marrow Transplant       Date:  2014-08-23       Impact factor: 5.742

10.  FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.

Authors:  Yeohan Song; John Magenau; Brian Parkin; Sung Won Choi; Yumeng Li; Thomas Braun; Lawrence Chang; Dale Bixby; David A Hanauer; Komal A Chughtai; Erin Gatza; Daniel Couriel; Steven Goldstein; Attaphol Pawarode; Pavan Reddy; Mary Riwes; James Connelly; Andrew Harris; Carrie Kitko; John Levine; Greg Yanik
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.